Posts by: Joana Fernandes

News

Interim results of a clinical trial evaluating Celsion’s GEN-1 combined with preoperative chemotherapy to treat patients with advanced ovarian cancer were recently presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting. The ... Read more

June 28, 2017

Half of Ovarian Cancer Patients Respond to Quisinostat Combo Therapy, Phase 2 Clinical Trial Shows

News

Half of patients with advanced ovarian cancer responded either fully or partially to a combination of quisinostat, Taxol (paclitaxel) and Paraplatin (carboplatin), according to a Phase 2 clinical trial. The ... Read more

June 23, 2017June 23, 2017

PharmaMar’s Lurbinectedin to Be Marketed as Zepsyre After Approval as Ovarian Cancer Therapy

News

Once approved, PharmaMar’s lurbinectedin (PM1183) will be marketed under the brand name Zepsyre as a treatment for solid tumors in ovarian, lung, and breast cancers. Zepsyre is in its final stage of development as ... Read more

June 2, 2017June 2, 2017

Blood Sugar and GLUT1 Protein May Be Biomarkers for Ovarian Cancer, Study Finds

News

Researchers studying blood glucose levels and the glucose transporter protein GLUT1 have discovered a potential biomarker for aggressive ovarian cancer. A study found that patients with lower blood glucose levels ... Read more

May 31, 2017

Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients

News

Tesaro will present three abstracts with results from the ENGOT-OV16/NOVA trial evaluating the effectiveness of Zejula (niraparib) in patients with recurrent ovarian cancer at the upcoming 2017 American Society of Clinical ... Read more

May 26, 2017

Oregovomab Combo Benefits Ovarian Cancers More Than Chemo Alone, Study Reports

News

Adding oregovomab to standard chemotherapy significantly increases the time it takes for a newly diagnosed advanced ovarian cancer patient to have their disease progress or die, according to a Phase ... Read more

April 26, 2017

Diplomat Pharmacy to Distribute Recently Approved PARP Inhibitor Zejula in the US

News

Diplomat Pharmacy will be one of the companies distributing Zejula (niraparib), a recently approved treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the United ... Read more

March 20, 2017March 20, 2017

Inhibiting DNA Repair Enzyme Called PARG Could Be Way to Fight Ovarian Cancer

News

Inhibiting the PARG enzyme could be a good way to fight ovarian cancer, according to a study. The research, “First-In-Class Chemical Probes Against Poly(ADP-Ribose) Glycohydrolase (PARG) Inhibit DNA Repair With ... Read more

February 17, 2017February 17, 2017

Tiny Vesicles in the Blood Might Distinguish Ovarian Cancers from Benign Tumors

News

Blood levels of a molecule called phosphatidylserine (PS) may help distinguish between malignant and benign ovarian tumors, researchers report. The study resulted from the collaboration between researchers at the University ... Read more

February 15, 2017

Osmium Compound Could Help Ovarian Cancer Patients Who Are Resistant to Platinum Therapies

News

An organometallic compound called Organo-Osmium FY26 may be a promising therapy for ovarian cancer, according to a study. Researchers said FY26, which includes the metal osmium, may be able to ... Read more